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Introduction
More than one million deaths per year are attributed to viral hepatitis infections worldwide.
The Global Burden of Disease (GBD) study showed that 1.2% of global deaths resulted from hepatitis in 2010. The total number of deaths resulting from hepatitis B was estimated to be 786,000 and that due to hepatitis C was 499,000 in 2010. Thus, hepatitis B and C were the 15th and 25th greatest causes of death, respectively (1) . Unlike hepatitis B and C, hepatitis A infection is rarely fatal, but it can cause debilitating symptoms or acute liver failure which is associated with high mortality (2) . Approximately 1.4 million cases of hepatitis globally occur every year. Furthermore, hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading causes of liver cancer worldwide, accounting for 78% of cases (1) . Especially, hepatitis B infection is known as one of the major causes of morbidity and mortality in Korea (3).
In Korea, hepatitis is usually caused by hepatitis A virus (HAV), HBV, and HCV, similar to other countries. These viruses are the major causes of acute and chronic hepatitis. Although HBV has been one of the major causes of acute hepatitis in the past, the incidence of HAV infection has increased rapidly in recent years in Korea (4) . These three hepatitis viruses can also lead to acute disease, with symptoms of nausea, abdominal pain, fatigue, malaise, and jaundice. Furthermore, HBV and HCV can establish chronic infections (5) . Patients with chronic infection are likely to develop the next stage of disease, such as cirrhosis and hepatocellular carcinoma (HCC) (6) .
Hepatitis B virus (HBV) infection is endemic in Korea (7). According to the Korean
National Health and Nutrition Examination Survey (KNHANES) conducted in 2010, the prevalence rate (hereinafter "prevalence") of HBsAg among people aged 10 or older is about A c c e p t e d M a n u s c r i p t 3 .0%. Following the implementation in the 1990s of a national HBV vaccination program for all neonates with HBsAg carrier mothers, the prevalence of HBV in the younger generation aged 10-18 dropped rapidly from approximately 4-5% in 1990s to 0.1% in 2010. However, the prevalence of HBV in people older than 30 years remains high (3.7% in 2010) (8) .
Due to the high prevalence in Korea, viral hepatitis infection has an effect not only on the population health status but also on national healthcare costs. However, no studies have examined the costs of hepatitis, including simultaneous estimation of the costs of hepatitis A, B, and C. This study was performed to estimate the economic costs of HAV, HBV, and HCV infection during 2008-2011 from a societal perspective, and to analyze recent trends in Korea using national data.
Materials and Methods

Prevalence and mortality rate
Here, the prevalence of hepatitis is defined as the total number of cases of hepatitis infection in the population, taken from the National Health Insurance Service (NHIS) claim data, divided by the total population, obtained from population projections by sex and age of the Korean Statistical Information Service (KOSIS) (9). The NHIS was independently established as a single-payer in health insurance system in Korea and the claim data includes entire population who used healthcare service. The KOSIS is a national statistical database, operated by Statistics Korea. It also produces official statistics to compare international organization such as IMF, World Bank, OECD.
The case with hepatitis infection based on a primary diagnosis from the claim data. To identify hepatitis cases, we used the International Classification of Disease (ICD)-10 code A c c e p t e d M a n u s c r i p t B15 for hepatitis A, from B16 to B19 (except B17.1 & B18.2) for hepatitis B and B17.1 and B18.2 were used for hepatitis C. The criteria for classification as a patient with hepatitis infection were at least one inpatient or outpatient claim over one year with a primary diagnosis of hepatitis A, B, or C. The mortality rate of hepatitis is defined as the number of deaths due to hepatitis infection based on the cause of death by sex and age given by KOSIS divided by the total population number taken from the KOSIS data of population projections by sex and age (9). Statistics are shown as the rate per 100,000 people.
Costs related to hepatitis A, B, and C virus infections are estimated using a prevalencebased approach, including the number of patients with hepatitis A, B, and C and the number of deaths resulting from hepatitis A, B, and C during the period from 2008 to 2011. Because there is a mandatory health insurance managed by the NHIS for residents in Korea, the claim data from NHIS represents the entire population of Korea (10) . Therefore, access to NHIS claims data allowed us to estimate overall medical expenditure for Korea as a whole. The method used to estimate the economic burden of disease was as follows.
The Economic Burden = Direct costs + Indirect costs
Direct costs
Direct costs consisted of direct medical care costs, including NHI-covered care costs, non-NHI-covered care costs and co-payments, and NHI-covered drug and transportation costs for inpatient and outpatient care. The NHI data included patient information according to primary diagnosis, and we calculated the number of patients, length of stay, and costs A c c e p t e d M a n u s c r i p t covered by NHI using NHIS claim data. The definition of patient with hepatitis infection was based on ICD-codes.
To estimate the non-NHI-covered care costs such as magnetic resonance imaging (MRI) and ultrasound examinations, we calculated the costs based on the Survey on the Benefit Coverage Rate of National Health Insurance 2011 (11) , whose purpose was to collect hospital cost data annually from sample hospitals by the NHIS. In this survey, 1,103 institutions were selected to estimate non-NHI-covered costs, which is 1.4% of total institutions in Korea. Because there are several types of institutions such as tertiary hospitals, general hospital, hospital and clinic in Korea, whole institutions were stratified into 10 subgroups before sampling for improving sampling accuracy. Then, the sample institutions were allocated using Neyman method which uses to allocate sample to strata based on the strata variances and similar sampling costs in the strata (12) . The following percentages of non-NHI-covered inpatient and outpatient care costs related to hepatitis A, B, and C were applied in this analysis: 23.58% and 22.17%, respectively, for hepatitis A; 24.17% and 20.40%, respectively, for hepatitis B; 14.15% and 26.07%, respectively, for hepatitis C.
We regarded transportation costs as costs related to hepatitis A, B, and C from the Korea Health Panel 2010 whose purpose is mainly to gather health service utilization and health expenditure. The average transportation cost of patients with certain infectious and parasitic diseases was applied to the analysis from the data. In this panel, about 8,000 households and their members were surveyed since 2004. The sample of the survey was taken via 2-stage cluster, stratified sampling with probability proportionate to size. In other words, size of regional level was firstly considered and the households were selected based on the order list A c c e p t e d M a n u s c r i p t at the second stage for sample allocation. For this, the panel data also represents the Korean population (13) .
Indirect costs
Indirect costs consist of opportunity costs lost as a result of medical care or premature death and caregiver costs. The opportunity costs were calculated based on the human capital approach (14) . Productivity loss for inpatient care was calculated considering the average daily wage by gender and age from KOSIS, which is the national statistical database (9), and the lengths of inpatient hospital stays from NHI claim data. To estimate productivity loss due to outpatient care, however, we replaced the average daily wage with one third of the average daily wage. Patients aged 19 years and under and those aged 65 years and older were not included in the working age group, so we only calculated productivity loss for patients 20-64 years of age (15) . The GDP deflator was used to estimate productivity loss during [2008] [2009] [2010] [2011] in the study.
For inpatient care, caregiver costs were calculated by multiplying the length of stay by the minimum daily wage ($58.82) for caregivers from the Korea Patient Helper Society which is a representative caregiver association in Korea (16) . For outpatient care, it was assumed that only patients 19 years or under and 65 years or over would require caregivers (15, 17) , and outpatient care was assumed to require approximately one third of the patient's daily working hours (18) .
In terms of productivity loss due to premature death, the number of deaths resulting from hepatitis A, B, and C were obtained from the KOSIS death statistics (9). Productivity loss due to premature death was regarded as potential income lost calculated based on gender and age A c c e p t e d M a n u s c r i p t status. Subjects were divided into three groups according to age: ≤19 years, 20-64 years, and ≥65 years.
Finally, the economic burden of disease was estimated as the sum of the direct costs and the indirect costs resulting from hepatitis A, B, and C. All costs measured were converted into US dollars using an exchange rate of US$1 = 1160.81 Korean Won (average exchange rate during the period 2008-2011) (19).
Results
The tendency of the prevalence of hepatitis A was inconsistent during the study period. The The mortality rate per 100,000 due to hepatitis A is slightly higher than those due to hepatitis B and C respectively. Although the overall mortality rate of hepatitis A tended to decrease, the mortality rate in 2009 was still more than twice those of hepatitis B and C respectively (Table 1 ; Fig. 1 
, 2).
With regard to gender and age status, the prevalence and mortality rates of hepatitis A was higher for male patients 20-64 years of age than for males in other age groups during the period from 2008 to 2011. However, the prevalence was higher for female patients 19 years of age and younger than for females in other age groups, and the mortality rate was higher for female patients aged 65 years and older than for other age groups during the same period. 
A c c e p t e d
M a n u s c r i p t overall hepatitis B prevalence per 100,000 also increased over the same period. However, the mortality rate per 100,000 due to hepatitis B changed little, remaining approximately 0.03 per 100,000.
By gender and age status, whereas the hepatitis B prevalence per 100,000 was higher for both male (1302.68 in 2011) and female (987.37 in 2011) patients between 20 years and 64 years of age than for other age groups over the study period, the mortality rate per 100,000 was higher for both male (0.09) and female (0.06) patients 65 years of age and older than for other age groups.
In terms of hepatitis C, the total number of treated cases increased during the period from With respect to gender-and age-related data, the prevalence was higher for both male and female patients 65 years of age and older than for the other age groups. Due to the increased prevalence, the mortality rate also was higher for both male and female patients 65 years of age and older than for other groups, with increases of 64% and 65%, respectively (Table 1 (Table 2 ).
According to gender and age group, the economic burden of hepatitis A for male patients ($41.8 million) aged 20-64 years was higher than that for females ($17.8 million), whereas the costs for female patients ($248 thousand) aged 65 and over were for approximately 1.7 times the costs of males in the same age group ($147 thousand) in 2008. Overall costs decreased, and similar tendencies were observed in other years. In 2011, the economic burden of male patients ($32.5 million) aged 20-64 years was higher than that of females ($11.5 million) in the same age group, whereas the costs associated with female patients ($120 thousand) aged 65 and older were higher than those for males of that age ($69 thousand) in 2011 ( Table 2) . Indirect costs were estimated to be approximately 53.4% of this total, with direct costs accounting for the remaining 46.6% in the same periods (Table 2 ).
According to gender and age group, the economic burden of hepatitis B for male patients ($370.9 million) aged 20-64 years was much higher than that for females ($105.2 million) of that age, and the costs for male patients ($7.7 million) aged 19 and under were approximately 1.7 times those for females in the same age group ($4.6 million) in 2008. Furthermore, in 2011, the burden associated with male patients ($433.3 million) aged 20-64 was much higher A c c e p t e d M a n u s c r i p t than that for females ($139.0 million), whereas the costs associated with female patients ($12.9 million) aged 65 and older were higher than those for males in the same age group ($10.2 million) ( Table 2 ).
The total economic cost of hepatitis C increased during the period from 2008 to 2011 (from $63.9 million to $90.7 million) (Fig. 4) . The total cost of hepatitis C per capita also increased, from $1.55 thousand in 2008 to $1.86 thousand in 2011. Direct costs were estimated to be approximately 58.0% of this total, with indirect costs counting for the remaining 42.0% in 2011 ( Table 2 ).
According to gender and age group, the economic burden of hepatitis C for male patients ($40.1 million) aged between 20 and 64 years was higher than that for females ($15.3 million), whereas the costs associated with female patients ($4.5 million) aged 65 and older were higher than those for males in the same age group ($3.7 million) in 2008. The overall cost increased during the observation period, and similar tendencies were also observed in other years. In 2011, the economic burden of male patients ($52.2 million) aged between 20 and 64 was higher than that of females ($26.0 million), whereas costs associated with female patients ($7.0 million) aged 65 and over were higher than those for males in the same age group ($5.3 million) in 2011 ( Table 2) .
Discussion
This study estimated the economic burdens of hepatitis A, B, and C simultaneously using In 2011, the economic burden of hepatitis B was approximately 13 and seven times higher than those of hepatitis A and hepatitis C, respectively. In particular, the increased cost burden of hepatitis B could be attributed to increased direct costs due to the use of oral antiviral drugs for chronic hepatitis B, such as entecavir, which has been covered by NHI since 2007.
The greatest economic burden of disease per capita was for hepatitis C, followed by B and then A. The per capita burden of hepatitis C was 1.6 times higher than that of hepatitis A, and the per capita burden of hepatitis B was 1.2 times higher than that of hepatitis A. The trends in direct costs per capita were similar to those in the total economic burden (hepatitis C, followed by B and then A). That is, the most costly disease for one person was hepatitis C, even though the total burden of disease was much larger for hepatitis B than for both hepatitis A and C respectively. One of the reasons is that some medicines such as Interferon-Alfa-A c c e p t e d M a n u s c r i p t 2a/Ribavirin which is the most used for hepatitis C are relatively expensive and when compared to the medicines for hepatitis A and B (20) .
Considering gender and age groupings, the prevalence was higher for male than female patients with hepatitis A and B, but the prevalence of hepatitis C was higher for female than for male patients. Although the prevalence of hepatitis A was higher for male patients between 20 and 64 years of age than for other age groups, its rate was higher in female patients aged 19 years and younger. For hepatitis B, both male and female patients between 20 and 64 years of age had higher incidence rates compared with other age groups.
Meanwhile, the mortality rates of hepatitis B and C were higher for both male and female patients 65 years of age and older than for other age groups, except for male patients with hepatitis A. In terms of hepatitis A, the mortality rate for male patients between 20 and 64 years of age was higher than those for the other age groups. Furthermore, although the prevalence and mortality rates of hepatitis B and C were usually higher for female patients than for male patients, those of hepatitis A were higher for male than female patients.
The burdens of disease for hepatitis A, B, and C was higher for male patients aged between 20 and 64 than for females, whereas those of female patients aged 65 years and older tended to be higher than those of males in the same age group for all types of hepatitis infection.
A few previous studies have examined the burden of hepatitis infection in Korea, mostly focusing on hepatitis B infection, which is regarded as endemic in Korea (21) . In 1997, the total economic burden of acute hepatitis B was $120.6 million, which was divided into two components, i.e., direct and indirect costs. Direct costs (including Western and traditional medicine, pharmacy, dietary supplements, and nursing care) were $68.6 million, and indirect costs (including transportation, time, opportunity costs of inpatient hospital days, job loss, A c c e p t e d M a n u s c r i p t reduced work productivity, and premature death) were $49.6 million. Additionally, the direct and indirect costs of chronic hepatitis B were $143.0 million and $76.4 million, respectively (3). In 2001, the medical costs of chronic hepatitis B were $62.7 million. Furthermore, chronic hepatitis B-related diseases were reported to place a significant cost burden on the Korean health system (22) . In 2005, the total costs of chronic hepatitis B were $456.1 million.
In this 2005 study, total costs were divided into direct costs (including formal and informal medical costs and transportation costs) and indirect costs (including time and productivity loss due to morbidity or premature death), which were $131.9 million and $324. Nevertheless, as the population has had fewer opportunities to develop anti-HAV antibodies through natural infection due to improved sanitation and living standards in Korea (25) , the number of cases of hepatitis A progressively increased before the early 2000s (26) . With regard to hepatitis C, HCV continues to be a major disease burden and is a cause of concern worldwide, especially in developing countries. Although most developed countries have low prevalence of hepatitis C, the rates still remain high in East Asian countries such as Korea and Japan (27) .
It is useful to compare our results with other studies in Korea that used similar methods to gain an understanding of the relative magnitudes of the economic burden of disease. Hepatitis A, B, and C have lower economic burdens compared to major diseases such as cancer, stroke, A c c e p t e d M a n u s c r i p t asthma, epilepsy, and musculoskeletal disease, whose costs range from $525.5 million to $6.9 billion (15, 17, 18, 28) . However, the sum of costs for hepatitis A, B, and C ($744.1 million) was higher than that for epilepsy ($525.5 million) (29) and only slightly less than that for asthma ($786.1 million) (15) . However, the economic burdens of colorectal cancer, stroke, and musculoskeletal disease were 4.1, 4.7, and 9.3 times greater than those of hepatitis infection, respectively (17, 28, 30) . approach to disease management is for the government to phase in management programs for selected hepatitis infections, taking the available budget into account. The total burden of disease, which reflects prevalence and mortality rates, would be a reasonable criterion for selecting diseases to receive such consideration. That is, an effective management policy should be planned and implemented to prevent and control the economic burden of hepatitis B in Korea. In effect, with an effective vaccine for hepatitis B, immunization has been a central strategy for most countries to reduce the burden of hepatitis B (36). In the same context, Korea already has a national immunization program for children to prevent hepatitis B infection. This program has already been provided at no cost through every health community center, is subsidized by the government at 30% in private hospitals (37), and was made available at no cost at all clinics beginning in January 2014 (38). Therefore, the prevalence of hepatitis B is decreasing for people aged 19 or under; however, the total number of patients with hepatitis B continues to increase. As the total hepatitis B burden will This study has some limitation. Firstly, the burden of hepatitis infection may be underestimated because main diagnosis code was used for calculating the case and mortality in this study. Second limitation was the reliance on the accuracy of NHI claim data, in which the burden of hepatitis was limited to cases where it was the primary diagnosis. Therefore, in case of people with hepatitis virus as a secondary diagnosis, it was not taken into account in the calculations. Third, health insurance claim data in general have coding accuracy issue when physicians diagnose disease with ICD-code including potential misclassification. The original purpose of claim data is claim rather than statistics. Finally, the prevalence of hepatitis can be slightly different from other statistics due to the employment of different data sources. For example, prevalence of hepatitis B aged 0-19 in this study which used NHIS claim data was a little bit higher than the statistics in other studies which employed KNHANES (39).
We analyzed the economic burden of disease related to hepatitis infection in Korea. This study was important in that we simultaneously considered the burdens of hepatitis A, B, and C. There have been few previous studies of hepatitis C infection. We also showed the trends for each disease based on long-term results. The costs associated with hepatitis A are still high even though the prevalence is decreasing. Among hepatitis infections, hepatitis B accounts for the greatest portion of the total economic burden of disease. We should continue to focus on hepatitis C, not only because the economic burden has increased steadily but also A c c e p t e d M a n u s c r i p t because HCV is the leading cause of cirrhosis and hepatocellular carcinoma in conjunction with HBV.
As the economic burdens of hepatitis B and C will increase with rising prevalence, implementation of effective prevention and management approaches is necessary.
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